Government Capacity

Equitable Innovation

06.26.24 | 1 min read

Racial and ethnic minorities needing medical care will enter sites of care and experience harm from biased medical technologies and interventions. Biases persist across the health innovation ecosystem with drugs, diagnostics, devices, algorithms, and care practices. FAS believes the federal government can play a critical role in correcting bias in technologies and incentivizing future processes for equitable innovation. FAS works to ensure the research and development process is open and fair, looks for ways to support market success for “equitable innovations”, and lifts up new health policy ideas from communities impacted by health inequities.

publications
See all
Emerging Technology
day one project
Policy Memo
In Honor of Patient Safety Day, Four Recommendations to Improve Healthcare Outcomes

Most patient safety challenges are not really captured and there are not enough tools to empower clinicians to improve. Here are four proposals for improving patient safety that are worthy of attention and action.

09.17.25 | 7 min read
read more
Government Capacity
day one project
Policy Memo
Protecting Infant Nutrition Security:
Shifting the Paradigm on Breastfeeding to Build a Healthier Future for all Americans

Policymakers on both sides of the aisle agree that no baby should ever go hungry, as evidenced by the bipartisan passage of recent breastfeeding legislation and widely supported regulations. However, significant barriers remain.

02.11.25 | 10 min read
read more
Emerging Technology
day one project
Policy Memo
Clearing the Path for New Uses for Generic Drugs

To encourage greater adoption of generic drugs in clinical practice the FDA should implement a dedicated regulatory pathway for non-manufacturers to seek approval of new indications for repurposed generic drugs.

01.09.25 | 16 min read
read more
Emerging Technology
day one project
Policy Memo
Slow Aging, Extend Healthy Life: New incentives to lower the late-life disease burden through the discovery, validation, and approval of biomarkers and surrogate endpoints

New solutions are needed to target diseases before they are life-threatening or debilitating, moving from retroactive sick-care towards preventative healthcare.  

12.09.24 | 15 min read
read more